Find a Provider

Adam D. Cohen, MD

Adam D. Cohen, MD Physician

Director, Myeloma Immunotherapy
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Cohen is a Penn Medicine employed physician.

Clinical Specialties

Specialties:

  • Medicine
    • Hematology
    • Medical Oncology

Programs & Services:

  • Cancer
    • Amyloidosis Program
    • Bone Marrow Transplant and Stem Cell Transplant Program
    • Leukemia
    • Multiple Myeloma
  • Hematology-Oncology
    • Classical (Non-Malignant) Hematology Program

Board Certification:

  • Hematology, 2007
  • Medical Oncology, 2005

Conditions & Treatments:

  • autologous transplant
  • Blood Cancer
  • bone marrow transplant
  • Multiple Myeloma
  • Waldenstrom macroglobulinemia

Clinical Interests

Multiple myeloma
Amyloidosis
Waldenstrom's macroglobulinemia
Monoclonal gammopathies
Autologous stem cell transplantation

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Care
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: University of Pennsylvania School of Medicine
Residency: Hospital of the University of Pennsylvania
Fellowship: Memorial Sloan-Kettering Cancer Center

Memberships

American Association for Cancer Research, National American Society of Clinical Oncology, National American Society of Hematology, National Amyloidosis Support Group, Philadelphia Chapter, Local Eastern Cooperative Oncology Group, National Independent Response Adjudication Committee (IRAC), ACE-MM-102 trial (NCT01997840), International International Myeloma Society, International Managing Myeloma (educational resource), National Society for Immunotherapy of Cancer (SITC), National The Myeloma Beacon (a patient advocacy website), National

Affiliation

Dr. Cohen is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Research Interests:

Cancer immunotherapy
Vaccines
Cellular therapy
Phase I trials

Selected Publications:

Waxman A, Mick R, Garfall AL, Cohen AD, Vogl DT, Stadtmauer EA, Weiss BM.: Classifying ultra-high risk smoldering myeloma Leukemia 29 : 751-753,2015.

Garfall AL, Dougherty AL, Vogl DT, Weiss BM, Cohen AD, Mick R, O'Doherty U, Stadtmauer EA.: Association between mobilization regimen and PFS after auto-SCT for multiple myeloma. Bone Marrow Transplantation 9 : 1439-41,2014.

Anderson, KC, Alsina, M, Bensinger, W, Biermann, JS, Cohen, AD, Devine, S, Djulbegovic, B, Faber, EA, Gasparetto, C, Hernandez-Illizaliturri, F, Huff, CA, Kassim, A, Krishnan, AY, Liedtke, M, Meredith, R, Raje, N, Schriber, J, Singhal, S, Somlo, G, Stockerl-Goldstein, K, Treon, SP, Weber, D, Yahalom, J, Yunus, F, Shead, DA, Kumar, R: Multiple Myeloma, Version 1.2013 Featured Updates to the NCCN Guidelines Journal Of The National Comprehensive Cancer Network 11 (1): 11-17,2013.

Schaer DA, Budhu S, Liu C, Bryson CF, Malandro NM, Cohen A, Zhong H, Yang X, Houghton AN, Merghoub T, Wolchok JD: GITR Pathway Activation Abrogates Tumor Immune Suppression Through Loss of Regulatory T cell Lineage Stability Cancer Immunology Research 1 : 320-31,2013.

Diab A, Jenq RR, Rizzuto GA, Cohen AD, Huggins DW, Merghoub T, Engelhorn ME, Guevara-PatiƱo JA, Suh D, Hubbard-Lucey VM, Kochman AA, Chen S, Zhong H, Wolchok JD, van den Brink MR, Houghton AN, Perales MA: Enhanced responses to tumor immunization following total body irradiation are time-dependent PLoS One 8 : e82496,2013.

Mentik-James A, Cohen AD, Campbell KC: Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells Frontiers in Immunology 4 : 481-,2013.

Anderson, KC, Alsina, M, Bensinger, W, Biermann, JS, Cohen, AD, Devine, S, Djulbegovic, B, Faber, EA, Gasparetto, C, Hernandez-Ilizaliturri, F, Huff, CA, Kassim, A, Krishnan, AY, Medeiros, BC, Meredith, R, Raje, N, Schriber, J, Singhal, S, Somlo, G, Stockerl-Goldstein, K, Treon, SP, Tricot, G, Weber, DM, Yahalom, J, Yunus, F, Kumar, R, Shead, DA: Waldenstrom''s Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013 Featured Updates to the NCCN Guidelines Journal Of The National Comprehensive Cancer Network 10 (10): 1211-1219,2012.

Cohen AD, Schaer DA, Wolchok JD: GITR. Encyclopedia of Cancer Targets : 2012.

Landau H, Pandit-Taskar N, Hassoun H, Cohen A, Lesokhin A, Lendvai N, Drullinsky P, Schulman P, Jhanwar S, Hoover E, Bello C, Riedel E, Nimer SD, Comenzo RL.: Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with International Staging System stage II or III, or extramedullary disease. Leukemia and Lymphoma 53 : 275-81,2012.

Cohen AD, Comenzo RL: Light-chain (AL) amyloidosis: diagnosis, prognosis, and therapy. Hematology (American Society of Hematology Educational Program) : 287-294,2010.

Academic Contact Info

Perelman Center for Advanced Medicine
2nd Floor, West Pavilion
3400 Civic Center Blvd

Philadelphia, PA 19104
Phone: (215) 615-5853
Fax: (215) 615-5887
Patient appointments: 800-789-PENN (7366)